412 related articles for article (PubMed ID: 27321333)
1. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
Kaneko M; Narukawa M
Diabetes Res Clin Pract; 2016 Jun; 116():171-82. PubMed ID: 27321333
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records.
Xie Y; Bowe B; Xian H; Loux T; McGill JB; Al-Aly Z
Lancet Diabetes Endocrinol; 2023 Sep; 11(9):644-656. PubMed ID: 37499675
[TBL] [Abstract][Full Text] [Related]
3. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.
Elgendy IY; Mahmoud AN; Barakat AF; Elgendy AY; Saad M; Abuzaid A; Wayangankar SA; Bavry AA
Am J Cardiovasc Drugs; 2017 Apr; 17(2):143-155. PubMed ID: 27873238
[TBL] [Abstract][Full Text] [Related]
5. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Gooßen K; Gräber S
Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
[TBL] [Abstract][Full Text] [Related]
6. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S
PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants.
Wu S; Hopper I; Skiba M; Krum H
Cardiovasc Ther; 2014 Aug; 32(4):147-58. PubMed ID: 24750644
[TBL] [Abstract][Full Text] [Related]
10. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
Chen M; Liu Y; Jin J; He Q
Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
Dawwas GK; Smith SM; Park H
Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
[TBL] [Abstract][Full Text] [Related]
13. Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs.
Fei Y; Tsoi MF; Kumana CR; Cheung TT; Cheung BMY
Int J Cardiol; 2018 Mar; 254():291-296. PubMed ID: 29277321
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
Zhang Y; Hong J; Chi J; Gu W; Ning G; Wang W
Diabetes Metab Res Rev; 2014 Mar; 30(3):241-56. PubMed ID: 24123720
[TBL] [Abstract][Full Text] [Related]
15. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.
Scirica BM; Im K; Murphy SA; Kuder JF; Rodriguez DA; Lopes RD; Green JB; Ruff CT; Sabatine MS
Clin Cardiol; 2022 Jul; 45(7):794-801. PubMed ID: 35715946
[TBL] [Abstract][Full Text] [Related]
16. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.
Zhao M; Sun S; Huang Z; Wang T; Tang H
Clin J Am Soc Nephrol; 2020 Dec; 16(1):70-78. PubMed ID: 33376101
[TBL] [Abstract][Full Text] [Related]
17. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study.
Baksh S; Wen J; Mansour O; Chang HY; McAdams-DeMarco M; Segal JB; Ehrhardt S; Alexander GC
Sci Rep; 2021 Aug; 11(1):16637. PubMed ID: 34404825
[TBL] [Abstract][Full Text] [Related]
19. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
20. Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH
Endocrinol Metab (Seoul); 2021 Apr; 36(2):388-400. PubMed ID: 33789035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]